Treatment for premature ejaculation depends on whether it is lifelong or acquired, whether erection difficulties are present and what outcome matters to you.
Premature ejaculation can be treated, but there is no single option that is right for everyone. A proper plan starts by confirming the pattern: lifelong PE is managed differently from a sudden, acquired change linked to erectile dysfunction, urinary symptoms, anxiety or another health problem.
A clinician should first establish whether ejaculation has always been early or whether it has changed. The assessment also considers erection quality, urinary or pelvic symptoms, current medicines, mental health, relationship context and the patient’s preferences.
For acquired PE, the EAU recommends addressing an underlying cause—such as erectile dysfunction, prostatitis, lower urinary tract symptoms, anxiety or hyperthyroidism—before treating ejaculation in isolation. For lifelong PE, pharmacological treatment is generally considered first line. The choice still depends on suitability and preference.
| Option | How it may help | Main limitations |
|---|---|---|
| Dapoxetine | An on-demand SSRI licensed in the UK for diagnosed PE in eligible men aged 18–64. | Not suitable with some medical conditions or medicines; dizziness, nausea, headache and fainting risk require screening. |
| Lidocaine/prilocaine spray | Temporarily reduces sensation at the glans and is used shortly before sex. | Can cause numbness, irritation, erectile difficulty or transfer to a partner; product-specific condom and fertility instructions matter. |
| Daily SSRIs or clomipramine | Delayed ejaculation is used therapeutically when a clinician prescribes one of these medicines off-label. | Most are not licensed specifically for PE in the UK and can cause adverse effects, interactions and withdrawal symptoms. |
| Psychosexual therapy | Addresses anxiety, avoidance, communication, expectations and patterns of arousal. | Requires engagement and access to a suitably qualified therapist; improvement is not immediate or guaranteed. |
| Behavioural techniques | Stop–start or squeeze practice may improve recognition of arousal and perceived control. | Evidence and durability vary, and repeated practice can feel disruptive or pressurised. |
| ED treatment when both occur | Improving erection reliability can reduce rushing and erection-related anxiety. | It does not directly treat every case of PE and must be selected safely after assessment. |
Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) licensed in the UK as an on-demand treatment for diagnosed PE in eligible adult men aged 18–64. It is not a daily antidepressant regimen and should not be used merely to make sex last longer in someone who has not been diagnosed with PE.
The UK patient leaflet gives 30 mg as the usual starting dose, taken one to three hours before anticipated sexual activity. A clinician may consider 60 mg only if the response and tolerability make that appropriate. It must not be taken more than once in 24 hours. Screening is important because dapoxetine can cause dizziness and fainting and interacts with several medicines.
Local anaesthetics reduce sensation at the head of the penis. Fortacin, a metered lidocaine/prilocaine spray, is licensed for primary PE in adult men. Other creams and sprays may have different instructions or may be used off-label.
Partner transfer, local irritation and excessive numbness are practical concerns. The product information for Fortacin also contains specific warnings about condom materials and trying to conceive. A patient should follow the leaflet for the exact product rather than applying generic online instructions.
Psychosexual therapy considers the whole sexual experience rather than ejaculation time alone. Sessions may address anxiety, avoidance, communication, unrealistic expectations, relationship strain or previous difficult experiences. A partner may attend if both people want this.
Current EAU guidance supports combining psychological or behavioural treatment with pharmacological treatment in acquired PE, although the recommendation is weaker than for licensed medicines in lifelong PE. Therapy may also be a reasonable first choice for situational or less troublesome symptoms.
In stop–start practice, stimulation pauses as ejaculation approaches and resumes after arousal has reduced. The squeeze technique adds brief pressure near the head of the penis before the point of inevitability. These methods require practice and should not become a performance test. Some people find them useful; others find that they interrupt intimacy or increase self-monitoring.
A psychosexual therapist can adapt the exercise and help a couple move away from a narrow focus on penetration or duration.
PE and erectile dysfunction frequently overlap. A man worried about losing an erection may rush sexual activity or reach ejaculation before the erection fades. The EAU recommends treating ED first when both conditions are present.
PDE5 inhibitors such as sildenafil or tadalafil primarily treat erectile dysfunction. Treating associated ED may improve acquired PE when erection anxiety is contributing. However, current UK product information states that dapoxetine should not be used with PDE5 inhibitors because orthostatic tolerance may be reduced. An erection medicine should not be assumed to correct PE.
Paroxetine, sertraline, fluoxetine and clomipramine can delay ejaculation and are sometimes prescribed for PE. In the UK, this is generally an off-label use. Off-label does not mean automatically unsafe or ineffective; it means the specific use is outside the medicine’s marketing authorisation. The prescriber should explain the evidence, alternatives, side effects and how the medicine should be started or stopped.
Do not use another person’s antidepressants or stop a daily antidepressant abruptly. Withdrawal effects and recurrence of a treated mental health condition need to be considered.
Tramadol can delay ejaculation, but it is an opioid with dependence and safety risks. EAU guidance places it as a cautious third-line, off-label option, not routine self-treatment. Penile injections of fillers and surgery aimed at reducing nerve sensitivity are not standard first-line options. The EAU advises against dorsal neurectomy because more safety evidence is needed.
Unregulated tablets, sprays and supplements may contain undeclared ingredients or inappropriate doses. UK prescription-only medicines should come from a regulated prescriber and pharmacy.
